MORGANTOWN, W.Va., Jan. 10, 2014 (GLOBE NEWSWIRE) -- Protea Biosciences Group, Inc. ("Protea"), a molecular information company whose proprietary technology platform enables direct molecular imaging for pharmaceutical and life science research, announced today that CEO Stephen Turner will present at the 7th Annual OneMedForum SF 2014 on Tuesday January 14, 2014 at 9:30 AM PST and the Biotech Showcase 2014 on Wednesday January 15, 2014 at 2:00 PM PST in San Francisco, California. Mr. Turner will discuss Protea's technology and commercial status and provide a corporate update. Exact details regarding Protea's presentations are below:
| Event: | 7th Annual OneMedForum SF 2014 | |
| Date: | January 14, 2014 | |
| Time: | 9:30 AM PST | |
| Location: | Franciscan I: The Westin San Francisco Market Street |
About OneMedForum
The OneMedForum has become one of the world's pre-eminent healthcare growth company conferences. It attracts over 1000 leading investors, entrepreneurs and executives who have the chance to meet management of promising investment opportunities. Its panels provide a means to meet thought leaders and to gain strategic insight into capitalizing on the rapidly changing financing environment for healthcare and life science companies.
| Event: | Biotech Showcase™ 2014 Conference | |
| Date: | January 15, 2014 | |
| Time: | 2:00 PM PST | |
| Location: | Room Hearst: Parc 55 Wyndham San Francisco Union Square Hotel |
About Biotech Showcase
Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences. Now in its sixth year, Biotech Showcase is expected to attract upwards of 1,500 attendees.
About Protea Biosciences Group, Inc.
Protea is a molecular information company, whose proprietary technology enables direct molecular Imaging – the ability to identify and display molecules in tissue and cells, without touching or pretreating samples. Protea delivers robust molecular information to customers focused on drug and life science research, and biomarker discovery
Protea website: https://proteabio.com/
About LAESI direct molecular imaging: https://proteabio.com/imaging/LAESI-MSI
Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements, as described in our reports filed with the Securities and Exchange Commission which are available for review at www.sec.gov, to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
| For more Information: | ||
| Protea Biosciences Group, Inc., | ||
| 955 Hartman Run Road, Morgantown, WV 26507 USA | ||
| Phone: 304.292.2226 | Fax: 304.292.7101 | |
| www.proteabio.com ; | ||
| Contact: steve.oloughlin@proteabio.com | ||
Protea and LAESI are registered Trademarks of Protea Biosciences Group, Inc.